Sobi to refile Gamifant following CHMP rejection
The company’s peak sales forecast of more than $500 million remains unchanged
Read More
Tag: emapalumab
Eleven medicines backed for EU approval
Recommendations include the first antibody-drug conjugate for multiple myeloma patients with limited treatment options
Read More
US OKs first treatment for haemophagocytic lymphohistiocytos
US regulators have approved Swedish Orphan Biovitrum (Sobi) and Novimmune’s Gamifant as the first treatment for the rare disorder primary haemophagocytic lymphohistiocytosis.
Read More
Novimmune submits lead drug emapalumab in Europe
Swiss biotech Novimmune has submitted a marketing application in Europe seeking permission to market its lead compound emapalumab for the treatment of patients with primary Hemophagocytic Lymphohistiocytosis (HLH).
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
